| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7803838 | ALLERGAN | Compositions comprising nebivolol |
Aug, 2026
(2 years from now) | |
| US7838552 | ALLERGAN | Compositions comprising nebivolol |
Oct, 2027
(4 years from now) | |
Byvalson is owned by Allergan.
Byvalson contains Nebivolol Hydrochloride; Valsartan.
Byvalson has a total of 2 drug patents out of which 0 drug patents have expired.
Byvalson was authorised for market use on 03 June, 2016.
Byvalson is available in tablet;oral dosage forms.
Byvalson can be used as method of treating hypertension.
The generics of Byvalson are possible to be released after 04 October, 2027.
Drugs and Companies using NEBIVOLOL HYDROCHLORIDE; VALSARTAN ingredient
Market Authorisation Date: 03 June, 2016
Treatment: Method of treating hypertension
Dosage: TABLET;ORAL
BYVALSON family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic